Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KYV-101 in Treatment Refractory Stiff Person Syndrome
NCT06588491Phase 2Completed
- Sponsor
- Kyverna Therapeutics
- Start
- Sep 2024
- Primary completion
- Jun 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mivocabtagene autoleucel in stiff person syndrome (SPS), sponsored by Kyverna Therapeutics. Primary endpoints: Efficacy of KYV-101 at 12 months and Safety of KYV-101 at 12 months. Started Sep 2024; status: completed.
02
Drugs
mivocabtagene autoleucel
03
Conditions
stiff person syndrome (SPS)
Beyond the preview
Go deeper on NCT06588491.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06588491.